# A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes and Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker

> **NCT01137474** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 2996 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** Dapagliflozin
- **DRUG:** Placebo-matching dapagliflozin

## Key facts

- **NCT ID:** NCT01137474
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-07
- **Primary completion:** 2013-02
- **Final completion:** 2013-02
- **Target enrollment:** 2996 (ACTUAL)
- **Last updated:** 2017-01-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01137474

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01137474, "A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes and Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT01137474. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*